Sarah Maria Leiter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah Maria Leiter has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Jamie Trotman
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
6 shared publications - Aditi Vedi
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
4 shared publications - Catherine Elizabeth Hook
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
4 shared publications - John Alphonse Tadross
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
4 shared publications - Matthew Jonathan Murray
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
4 shared publications - Sam Behjati
Wellcome Sanger Institute, Hinxton, UK
4 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10078
Rapid Whole Genome Sequencing Enhances Pediatric Cancer Diagnosis
Whole-genome sequencing (WGS) has been shown to improve diagnosis beyond standard-of-care genetic tests and guide precision treatment for childhood cancer. While WGS is now offered for children with suspected cancer in England, clinical workflows typically return results after several weeks whereas clinical decisions are often required within days. Here we evaluate feasibility and efficacy of a rapid WGS (rWGS) research workflow with streamlined bioinformatics to deliver clinical genomic findings (NCT07201038, Active, not recruiting). In 54 children with suspected or confirmed malignancy, rWGS reduces mean end-to-end turnaround time from 42 to 3 days, whilst increase variant detection rate. Whereby rWGS detected 147 of 155 (95%) clinically actionable variants identified in the cohort, standard of care testing detected 138 of 155 (89%) variants. In a subset of 35 patients assessed prospectively, clinicians report that in 17 (49%), rWGS either (i) facilitates faster access to targeted therapy and risk stratification, or (ii) avoids unnecessary investigations and treatment escalation. These findings indicate feasibility and suggest clinical utility of rWGS when deployed as a first line diagnostic test in pediatric oncology.
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10078
Open AccessRapid Whole Genome Sequencing Enhances Pediatric Cancer Diagnosis
Whole-genome sequencing (WGS) has been shown to improve diagnosis beyond standard-of-care genetic tests and guide precision treatment for childhood cancer. While WGS is now offered for children with suspected cancer in England, clinical workflows typically return results after several weeks whereas clinical decisions are often required within days. Here we evaluate feasibility and efficacy of a rapid WGS (rWGS) research workflow with streamlined bioinformatics to deliver clinical genomic findings (NCT07201038, Active, not recruiting). In 54 children with suspected or confirmed malignancy, rWGS reduces mean end-to-end turnaround time from 42 to 3 days, whilst increase variant detection rate. Whereby rWGS detected 147 of 155 (95%) clinically actionable variants identified in the cohort, standard of care testing detected 138 of 155 (89%) variants. In a subset of 35 patients assessed prospectively, clinicians report that in 17 (49%), rWGS either (i) facilitates faster access to targeted therapy and risk stratification, or (ii) avoids unnecessary investigations and treatment escalation. These findings indicate feasibility and suggest clinical utility of rWGS when deployed as a first line diagnostic test in pediatric oncology.
- Open Access
- 22 June 2026
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 26 (1) , 227
Observation of risk perception, knowledge and behaviour related to covid-19 in heart failure patients enrolled on a telecoaching program
Background: Telemedical interventions have been shown to reduce mortality and morbidity and improve the quality of life of chronic heart failure (CHF) patients. During the Covid-19 pandemic remote coaching gained further importance; however, it is not clear if Covid-19-specific telecoaching has a long-lasting impact on behaviour change. Methods: Patients were pre-existing participants in a combined tele-monitoring and telecoaching programme for CHF. A total of 419 patients were assessed with a standardised questionnaire immediately before and three weeks after a COVID-19-specific telecoaching in April 2020, as well as eight months later. The aim of the study was to observe changes in knowledge and behaviour regarding COVID-19 risk reduction measures, number of medical contacts and self-perceived health risk over time following the telecoaching module. Results: After telecoaching, patients spontaneously recalled significantly more COVID-19-specific risk reduction measures rising from an average of 2.1 items prior to coaching to 2.5 at short- and long-term follow-up ( p = 0.0002). The number of self-reported medical contacts were significantly lower at short-term than at long-term follow-up (30% vs. 42%, p = 0.0060 family doctor, 5% vs. 12%, p = 0.0014 hospital). CHF patients perceived themselves as low risk for a severe COVID-19 infection, and this perception did not change after telecoaching. No difference in social isolation or concern over time were noted. Conclusions: Our longitudinal observational study suggests a possible effect of a single COVID-19-specific telecoaching module on knowledge about the disease and complying with risk reduction measures, which seems to persist over time. These results should be interpreted with caution in the context of increasing public awareness and public health campaigns.
- 22 June 2026
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 26 (1) , 227
Open AccessObservation of risk perception, knowledge and behaviour related to covid-19 in heart failure patients enrolled on a telecoaching program
Background: Telemedical interventions have been shown to reduce mortality and morbidity and improve the quality of life of chronic heart failure (CHF) patients. During the Covid-19 pandemic remote coaching gained further importance; however, it is not clear if Covid-19-specific telecoaching has a long-lasting impact on behaviour change. Methods: Patients were pre-existing participants in a combined tele-monitoring and telecoaching programme for CHF. A total of 419 patients were assessed with a standardised questionnaire immediately before and three weeks after a COVID-19-specific telecoaching in April 2020, as well as eight months later. The aim of the study was to observe changes in knowledge and behaviour regarding COVID-19 risk reduction measures, number of medical contacts and self-perceived health risk over time following the telecoaching module. Results: After telecoaching, patients spontaneously recalled significantly more COVID-19-specific risk reduction measures rising from an average of 2.1 items prior to coaching to 2.5 at short- and long-term follow-up ( p = 0.0002). The number of self-reported medical contacts were significantly lower at short-term than at long-term follow-up (30% vs. 42%, p = 0.0060 family doctor, 5% vs. 12%, p = 0.0014 hospital). CHF patients perceived themselves as low risk for a severe COVID-19 infection, and this perception did not change after telecoaching. No difference in social isolation or concern over time were noted. Conclusions: Our longitudinal observational study suggests a possible effect of a single COVID-19-specific telecoaching module on knowledge about the disease and complying with risk reduction measures, which seems to persist over time. These results should be interpreted with caution in the context of increasing public awareness and public health campaigns.
- 23 April 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (7) , e70357
Somatic PLCG1 Mutation in a Vascular Tumor of an Infant
- 23 April 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (7) , e70357
Somatic PLCG1 Mutation in a Vascular Tumor of an Infant
- Open Access
- 17 October 2025
- Published by Springer Nature in Research Square
Clinical Impact of Ultra-Fast Whole Genome Sequencing in Paediatric Haematology-Oncology Practice
Whole genome sequencing (WGS) improves childhood cancer diagnosis, enabling precision treatment. However, timely clinical decisions are made within days, while WGS clinical reports using current technologies and workflows, can exceed 6 weeks. Here we report an ‘Ultra-fast WGS (UF-WGS)’ workflow, providing rapid and acurate molecular profiling of childhood malignancies. In 54 children with suspected or confirmed cancer, UF-WGS reduced turnaround time from 37 to 3 days. It captured 95% of clinically actionable variants found by conventional methods, and identified 19 additional actionable variants. UF-WGS led to demonstrable improvements in care for 51% of prospective patients, including avoidance of over-medicalisation and support for timely precision therapy. UF-WGS was feasible across diverse tumour types and sample sources, with additional technical advantages in variant detection and workflow simplicity. These findings indicate UF-WGS can significantly improve the management of paediatric haematology/oncology patients, specifically through precision diagnosis, risk stratification and molecularly informed treatment escalation/de-escalation.
- 17 October 2025
- Published by Springer Nature in Research Square
Open AccessClinical Impact of Ultra-Fast Whole Genome Sequencing in Paediatric Haematology-Oncology Practice
Whole genome sequencing (WGS) improves childhood cancer diagnosis, enabling precision treatment. However, timely clinical decisions are made within days, while WGS clinical reports using current technologies and workflows, can exceed 6 weeks. Here we report an ‘Ultra-fast WGS (UF-WGS)’ workflow, providing rapid and acurate molecular profiling of childhood malignancies. In 54 children with suspected or confirmed cancer, UF-WGS reduced turnaround time from 37 to 3 days. It captured 95% of clinically actionable variants found by conventional methods, and identified 19 additional actionable variants. UF-WGS led to demonstrable improvements in care for 51% of prospective patients, including avoidance of over-medicalisation and support for timely precision therapy. UF-WGS was feasible across diverse tumour types and sample sources, with additional technical advantages in variant detection and workflow simplicity. These findings indicate UF-WGS can significantly improve the management of paediatric haematology/oncology patients, specifically through precision diagnosis, risk stratification and molecularly informed treatment escalation/de-escalation.
- Open Access
- 14 October 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (1) , 99-107
Patient passports for rare diseases: results of a pilot study
For individuals with rare diseases, complex needs requiring multidisciplinary management can cause disjointed healthcare and challenges communicating with healthcare professionals (HCPs). ‘Patient passports’ support communication and healthcare coordination by sharing healthcare information with HCPs, reducing burden on patients/caregivers. Currently, no widely adopted passport addresses the multifaceted needs of patients with rare diseases. This pilot study was a service evaluation of a rare-disease-specific patient passport, co-designed with patients and HCPs. Patients/caregivers completed surveys before (‘pre-passport’) and after (‘post-passport’) using the passport. HCPs were surveyed on their perception of the passport. Of 157 ‘pre-passport’ survey respondents, 96.2% spent considerable time explaining medical needs to new care teams; 65.6% found communicating care needs challenging. Nearly all respondents (99.4%) believed a document presenting relevant healthcare information would be helpful. Among 55 ‘post-passport’ survey respondents, 85.1% used the passport during care interactions; 72.2% found it eased communication with unfamiliar teams, and 64.2% felt more confident communicating their needs. Over half (53.8%) felt the passport helped access needed care, 67.9% found it more useful than existing tools, and 75.9% were highly likely to recommend it to peers. All 31 HCP respondents listed perceived benefits, including improved HCP-patient/caregiver communication; some noted a preference for formal endorsement. By alleviating patient/caregiver-HCP communication challenges, this rare-disease-specific patient passport can enhance healthcare coordination and patient experiences. Participants’ use of the passport during interactions with care teams and likelihood of recommendation to peers support its widespread integration. Further work to assess usability across healthcare settings and to gain formal endorsement is warranted.
- 14 October 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (1) , 99-107
Open AccessPatient passports for rare diseases: results of a pilot study
For individuals with rare diseases, complex needs requiring multidisciplinary management can cause disjointed healthcare and challenges communicating with healthcare professionals (HCPs). ‘Patient passports’ support communication and healthcare coordination by sharing healthcare information with HCPs, reducing burden on patients/caregivers. Currently, no widely adopted passport addresses the multifaceted needs of patients with rare diseases. This pilot study was a service evaluation of a rare-disease-specific patient passport, co-designed with patients and HCPs. Patients/caregivers completed surveys before (‘pre-passport’) and after (‘post-passport’) using the passport. HCPs were surveyed on their perception of the passport. Of 157 ‘pre-passport’ survey respondents, 96.2% spent considerable time explaining medical needs to new care teams; 65.6% found communicating care needs challenging. Nearly all respondents (99.4%) believed a document presenting relevant healthcare information would be helpful. Among 55 ‘post-passport’ survey respondents, 85.1% used the passport during care interactions; 72.2% found it eased communication with unfamiliar teams, and 64.2% felt more confident communicating their needs. Over half (53.8%) felt the passport helped access needed care, 67.9% found it more useful than existing tools, and 75.9% were highly likely to recommend it to peers. All 31 HCP respondents listed perceived benefits, including improved HCP-patient/caregiver communication; some noted a preference for formal endorsement. By alleviating patient/caregiver-HCP communication challenges, this rare-disease-specific patient passport can enhance healthcare coordination and patient experiences. Participants’ use of the passport during interactions with care teams and likelihood of recommendation to peers support its widespread integration. Further work to assess usability across healthcare settings and to gain formal endorsement is warranted.
- Open Access
- 17 November 2024
- Published by Wiley in British Journal of Haematology
- Vol. 206 (1) , 204-208
Real‐world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland
Summary: Acute promyelocytic leukaemia (APL), defined by the t(15;17)(q24;q21) translocation, accounts for 5%–10% of paediatric acute myeloid leukaemia cases. All‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) are key treatments, though ATO access varies. We evaluated treatment, complications and survival in 50 UK paediatric APL patients diagnosed between 2014 and 2021. All patients received ATRA and most received ATO. Event‐free survival was lower in high‐risk patients (85% vs. 100%, p = 0.03), and those not receiving ATO at diagnosis. All relapsed patients could be salvaged with ATO. Addressing ATO availability and consistent funding is crucial to ensure timely treatment and improve outcomes.
- 17 November 2024
- Published by Wiley in British Journal of Haematology
- Vol. 206 (1) , 204-208
Open AccessReal‐world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland
Summary: Acute promyelocytic leukaemia (APL), defined by the t(15;17)(q24;q21) translocation, accounts for 5%–10% of paediatric acute myeloid leukaemia cases. All‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) are key treatments, though ATO access varies. We evaluated treatment, complications and survival in 50 UK paediatric APL patients diagnosed between 2014 and 2021. All patients received ATRA and most received ATO. Event‐free survival was lower in high‐risk patients (85% vs. 100%, p = 0.03), and those not receiving ATO at diagnosis. All relapsed patients could be salvaged with ATO. Addressing ATO availability and consistent funding is crucial to ensure timely treatment and improve outcomes.
- 8 October 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31368
A diagnosis of Noonan syndrome through routine whole genome sequencing in a child with an intracranial nongerminomatous germ cell tumor
- 8 October 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31368
A diagnosis of Noonan syndrome through routine whole genome sequencing in a child with an intracranial nongerminomatous germ cell tumor
- 8 August 2024
- Published by Elsevier in Clinical Oncology
- Vol. 38, 103623
Developing a Paired Whole Genome Sequencing Service for Children With Cancer
- 8 August 2024
- Published by Elsevier in Clinical Oncology
- Vol. 38, 103623
Developing a Paired Whole Genome Sequencing Service for Children With Cancer
- Open Access
- 2 July 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (7) , 1905-1912
Benefits for children with suspected cancer from routine whole-genome sequencing
Clinical whole-genome sequencing (WGS) has been shown to deliver potential benefits to children with cancer and to alter treatment in high-risk patient groups. It remains unknown whether offering WGS to every child with suspected cancer can change patient management. We collected WGS variant calls and clinical and diagnostic information from 281 children (282 tumors) across two English units (n = 152 from a hematology center, n = 130 from a solid tumor center) where WGS had become a routine test. Our key finding was that variants uniquely attributable to WGS changed the management in ~7% (20 out of 282) of cases while providing additional disease-relevant findings, beyond standard-of-care molecular tests, in 108 instances for 83 (29%) cases. Furthermore, WGS faithfully reproduced every standard-of-care molecular test (n = 738) and revealed several previously unknown genomic features of childhood tumors. We show that WGS can be delivered as part of routine clinical care to children with suspected cancer and can change clinical management by delivering unexpected genomic insights. Our experience portrays WGS as a clinically impactful assay for routine practice, providing opportunities for assay consolidation and for delivery of molecularly informed patient care.
- 2 July 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (7) , 1905-1912
Open AccessBenefits for children with suspected cancer from routine whole-genome sequencing
Clinical whole-genome sequencing (WGS) has been shown to deliver potential benefits to children with cancer and to alter treatment in high-risk patient groups. It remains unknown whether offering WGS to every child with suspected cancer can change patient management. We collected WGS variant calls and clinical and diagnostic information from 281 children (282 tumors) across two English units (n = 152 from a hematology center, n = 130 from a solid tumor center) where WGS had become a routine test. Our key finding was that variants uniquely attributable to WGS changed the management in ~7% (20 out of 282) of cases while providing additional disease-relevant findings, beyond standard-of-care molecular tests, in 108 instances for 83 (29%) cases. Furthermore, WGS faithfully reproduced every standard-of-care molecular test (n = 738) and revealed several previously unknown genomic features of childhood tumors. We show that WGS can be delivered as part of routine clinical care to children with suspected cancer and can change clinical management by delivering unexpected genomic insights. Our experience portrays WGS as a clinically impactful assay for routine practice, providing opportunities for assay consolidation and for delivery of molecularly informed patient care.
- 8 February 2024
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
- Vol. 109 (3) , 147-150
Implementation of preductal and postductal oxygen saturation screening in babies born in a district general hospital
Congenital heart defects (CHD) are the most common congenital anomaly and range from asymptomatic to lethal.1 2 Early recognition is critical to prevent postnatal collapse as CHD account for nearly 10% of neonatal deaths.1
- 8 February 2024
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
- Vol. 109 (3) , 147-150
Implementation of preductal and postductal oxygen saturation screening in babies born in a district general hospital
Congenital heart defects (CHD) are the most common congenital anomaly and range from asymptomatic to lethal.1 2 Early recognition is critical to prevent postnatal collapse as CHD account for nearly 10% of neonatal deaths.1